129 related articles for article (PubMed ID: 27272765)
1. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.
Xiao L; Lanz RB; Frolov A; Castro PD; Zhang Z; Dong B; Xue W; Jung SY; Lydon JP; Edwards DP; Mancini MA; Feng Q; Ittmann MM; He B
Prostate; 2016 Oct; 76(14):1271-84. PubMed ID: 27272765
[TBL] [Abstract][Full Text] [Related]
2. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
3. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
Kacprzyk LA; Laible M; Andrasiuk T; Brase JC; Börno ST; Fälth M; Kuner R; Lehrach H; Schweiger MR; Sültmann H
PLoS One; 2013; 8(3):e59976. PubMed ID: 23555854
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors.
Zhang Z; Lanz RB; Xiao L; Wang L; Hartig SM; Ittmann MM; Feng Q; He B
Oncotarget; 2016 Jun; 7(25):37993-38003. PubMed ID: 27191272
[TBL] [Abstract][Full Text] [Related]
5. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Yamoah K; Lal P; Awasthi S; Naghavi AO; Rounbehler RJ; Gerke T; Berglund AE; Pow-Sang JM; Schaeffer EM; Dhillon J; Park JY; Rebbeck TR
Prostate; 2021 Feb; 81(2):109-117. PubMed ID: 33141952
[TBL] [Abstract][Full Text] [Related]
7. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
8. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
9. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
[TBL] [Abstract][Full Text] [Related]
10. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
12. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
13. DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
Tolkach Y; Zarbl R; Bauer S; Ritter M; Ellinger J; Hauser S; Hüser L; Klauck SM; Altevogt P; Sültmann H; Dietrich D; Kristiansen G
Am J Pathol; 2021 Apr; 191(4):618-630. PubMed ID: 33485866
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
16. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
17. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
18. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer.
Shinde D; Albino D; Zoma M; Mutti A; Mapelli SN; Civenni G; Kokanovic A; Merulla J; Perez-Escuredo J; Costales P; Morìs F; Catapano CV; Carbone GM
Eur Urol Oncol; 2019 Jul; 2(4):415-424. PubMed ID: 31277777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
